Will the malaria vaccine be accepted in Pakistan after the experience of Covid-19 experience?

Authors

  • Hamza Nauman Fourth Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan
  • Aabia Zakai Fourth Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan
  • Anusha Anwer Fourth Year MBBS Student, Dow University of Health Sciences, Karachi, Pakistan

DOI:

https://doi.org/10.47391/JPMA.6910

Abstract

Malaria, caused by Plasmodium species is transmitted by a female Anopheles mosquito. It is the second highest ranking reported disease in the public sectors in Pakistan infecting 4 million people annually.1 The struggle for a vaccine providing protection against malaria finally was successful when WHO recommended widespread usage of the newly developed RTS,S/AS01 (RTS,S) malaria vaccine for children at risk. The vaccine’s efficacy against all clinical episodes of malaria was 51% for children in the age range of 5–17 months after a year following the first 3 doses.2

---Continue

Downloads

Published

2022-10-15

How to Cite

Hamza Nauman, Zakai, A., & Anusha Anwer. (2022). Will the malaria vaccine be accepted in Pakistan after the experience of Covid-19 experience?. Journal of the Pakistan Medical Association, 72(11), 2371–2371. https://doi.org/10.47391/JPMA.6910

Issue

Vol. 72 No. 11 (2022): NOVEMBER

Section

LETTER TO THE EDITOR